The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, Spain. Abstract submission is open until the 31st August 2017.
Academic and industrial researchers are welcome to join the workshop. For instance an industrial forum is organized to exchange ideas and network. People can also submit abstracts to participate to the poster session.
Organized by CIC biomaGUNE, the workshop will cover topics related to molecular imaging. The MIW2017 is the opportunity to discuss molecular imaging applications to neurosciences and oncology. Do not miss the sessions dedicated to cardiovascular application, infection tracking and pneumology.
The PneumoNP project will also attend the event. Attendees will be updated of the latest results of the project.
Several invited speakers are already announced. Jesús Ruíz Cabello from the Complutense University of Madrid, Spain, will give a lecture on the “characterization of metabolic reprogramming in pulmonary hypertension”. Jason Holland will come from Zurich to discuss “PET radiotracers for imaging oncogenic signaling pathways”.
The full list of invited speakers is available on the MIW2017 website.
You can already submit your abstract for the MIW2017 and so until the 31st August 2017. All abstracts must be related to one of the following categories:
- Infectious diseases and metabolism
- Imaging technology, methodology and data analysis
- Imaging probes
- Pulmonology and respiratory
Changes in the application are accepted until the submission deadline. So, do not wait and submit your abstract on the MIW2017 website.
Follow the PneumoNP team from event to event
The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in ...Read More
PneumoNP partners will attend ECCMID 2017 in Vienna, Austria, from 22-25th April 2017. ECCMID is a major event for experts ...Read More
Each year, European Antibiotic Awareness Day's campaigns encourage the prudent use of antibiotics on 18 November. Prudent use means only ...Read More
An experiment carried out in Spain shows the distribution of an inhaled nanomedicine in rat lungs.
The PneumoNP project aims at developing new inhaled nanotherapeutic formulations to combat lung infection. The novel drug is comprised of an antibiotic carried by a nanoparticle. For this project, Spanish researchers from CIC BiomaGUNE track the location of the therapeutic particles in rat airways.
The use of nanoparticles in formulations is anticipated to lengthen the residence time of the drug in lungs. Indeed, it is expected to slow down and control the release of the active molecules. This prevents rapid metabolism and fast clearance. So, the therapeutic effects are expected to increase. Besides, the delivery by inhalation contributes to diminish undesired toxicological and off-target side effects. The results obtained in imaging experiments are essential to establish the appropriate dosage to be used in therapeutic experiments with infected animals and to predict therapeutic efficacy.
Positron emission tomography image showing the regional distribution of aerosolized nanocarrier-antibiotic formulation in rat lung.
The researchers have developed labeling methods to incorporate different radionuclides to the nanocarrier and the antibiotic. Thanks to the different physical properties of the radionuclides, they visualize the spatiotemporal distribution of the nanocarrier and the antibiotic separately. To achieve that they also used complementary in vivo imaging modalities.
From imaging experiments, relevant information can be determined quantitatively by using only few experimental animals and extremely refined procedures. The percentage of administered dose that reaches the lungs is important to assess the efficacy of the aerosol delivery method. The researcher looks also for the regional distribution of the antibiotic and the nanocarrier within the lungs. With the spatiotemporal imaging, they evaluated the residence time of the active drug and the nanocarrier in the lungs.
Read related PneumoNP news
A delivery device for a breathable drug has been prototyped to test a new drug formulation. It aims to fight ...Read More
The antimicrobial peptide M33 may be the long-sought substitute to treat difficult lung infections, like multi-drug resistant pneumonia. In 2013, ...Read More
In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate Abstract: A synthetic ...Read More
Fine nanosystems carrying Meropenem and antimicrobial peptides to fight pulmonary infections are ready for in vitro tests. Before 2016 starts, ...Read More